Development of a novel Schiff base derivative for enhancing the anticancer potential of 5-aminolevulinic acid-based photodynamic therapy.

Abstract

5-Aminolevulinic acid (ALA), a precursor of protoporphyrin IX (PpIX), is now widely used for photodynamic diagnosis (ALA-PDD) and photodynamic therapy (ALA-PDT) of various cancers. Recently, we found that treatment of cancer cells with the Schiff base derivative TX-816 along with ALA could significantly increase the efficacy of ALA-PDT. This enhancing effect of TX-816 on ALA-PDT is attributed to 3,5-dichlorosalicylaldehyde (DCSA), a molecule produced by the degradation of TX-816. Similar to TX-816, DCSA significantly enhances the effect of ALA-PDT. Furthermore, DCSA could restore the sensitivity of cancer cells that acquired resistance to ALA-PDT. These results indicate that DCSA, as well as TX-816, is a potent lead compound for the development of an ALA-PDT sensitizer. TX-816 might be a useful compound for designing prodrug-type ALA-PDT enhancers.

• Authors: Yusei Shinohara, Yoshio Endo, Chiaki Abe, Ikkyu Shiba, Masahiro Ishizuka, Tohru Tanaka, Yutaka Yonemura, Shun-Ichiro Ogura, Masahide Tominaga, Hisatsugu Yamada, Yoshihiro Uto
• Journal: Photodiagnosis and photodynamic therapy (Photodiagnosis Photodyn Ther) Vol. 20 Pg. 182-188 (Dec 2017) ISSN: 1873-1597 [Electronic] Netherlands
• PMID: 29056554 (Publication Type: Journal Article)
• Copyright: Copyright © 2017 Elsevier B.V. All rights reserved.

Chemical References

• Photosensitizing Agents
• Schiff Bases
• Aminolevulinic Acid

Topics

• Aminolevulinic Acid (administration & dosage, pharmacology)
• Cell Line, Tumor
• Drug Synergism
• Drug Therapy, Combination
• Humans
• Photochemotherapy (methods)
• Photosensitizing Agents (administration & dosage, pharmacology)
• Schiff Bases (pharmacology)